Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449078 | 1.00 | P2RX7 (0.63) | P2RX7ABCB11 | |
| SCHEMBL5710576 | 1.00 | P2RX7 (0.63) | P2RX7ABCB11 | |
| Hydrochloric Acid SCHEMBL5710666 | 0.99 | P2RX7 (0.62) | P2RX7ABCB11 | |
| Hydrochloric Acid SCHEMBL5710696 | 0.99 | P2RX7 (0.62) | P2RX7ABCB11 | |
| SCHEMBL6365036 | 0.90 | P2RX7 (0.62) | P2RX7ABCB11 | |
| SCHEMBL5710408 | 0.90 | P2RX7 (0.62) | P2RX7ABCB11 | |
| SCHEMBL5710533 | 0.90 | P2RX7 (0.62) | P2RX7ABCB11 | |
| SCHEMBL5433736 | 0.90 | P2RX7 (0.51) | P2RX7ABCB11 | |
| SCHEMBL5138454 | 0.90 | P2RX7 (0.51) | P2RX7ABCB11 | |
| SCHEMBL5077420 | 0.90 | P2RX7 (0.66) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | claimed |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | claimed |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| JP-2007501270-A | — | — | 2007-01-25 | — | — | JP | claimed |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| EP-1448195-B1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | EP | claimed |
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | claimed |
| US-7129246-B2 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | claimed |
| EP-1644042-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | claimed |
| EP-1633401-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | claimed |
| EP-1596847-A1 | NEW COMBINATION | AstraZeneca AB (SE) | 2005-11-23 | — | — | EP | claimed |
| US-20050010052-A1 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | claimed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004073704-A1 | NEW COMBINATION | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | claimed |
| EP-1448195-A1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | claimed |
| WO-2003041707-A1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | claimed |
| EP-3402469-B1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INST NAT SANTE RECH MED (FR) | 2021-01-06 | — | — | EP | disclosed |
| WO-2003041707-A1 | N-ADAMANTYLMETHYL DERIVATES AND INTERMEDIATES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281931-A1 | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate | P2RX7, P2RY1, P2RX5 | P2RX7 1/4885ABCB11 184/4885 |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 267/4885 |
| US-20070082930-A1 | Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug | P2RX7, P2RX3, P2RX5 | P2RX7 1/4885ABCB11 159/4885 |
| US-20060247257-A1 | Combination | P2RX7, PCSK9, P2RX1 | P2RX7 1/4885ABCB11 317/4885 |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | P2RY1, P2RX3, P2RX7 | P2RX7 3/4885ABCB11 342/4885 |
| US-20070032465-A1 | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885ABCB11 345/4885 |
| US-20050010052-A1 | N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | ADRA1A, ADRA1D, ADORA1 | P2RX7 1517/4885ABCB11 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.